Divi's Laboratories
Market cap ₹2.38 L Cr
- P/E
- 81.21
- Day range
- ₹8,797.00 – ₹9,175.50
- 52-week range
- ₹5,647.50 – ₹9,740.00
- Volume
- 6.20 L
- Open
- ₹9,165.00
- Prev close
- ₹9,162.00
Latest results · Q1 FY27(consolidated)Revenue ₹3,080 Cr+27.8%Profit ₹902 Cr+65.5%Margin 29.3%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoters selling in the market
Promoter group sold a net ₹16.8 Cr on the open market in 90 days · 11 Aug 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
DIVISLAB in NSE indices and F&O
F&O margin for one lot of DIVISLAB (100 shares)Research profile
Composite 68 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.2%
- Graham no.
- ₹1,247.88
- vs Graham
- -86.1%
- ROE ÷ P/B
- 1.1%
- 12-1 mom.
- +42.5%
- Return / vol
- 1.51
- Magic Formula
- #419
- Piotroski
- 2/6
- FCF yield
- 0.1%
- PEG
- 6.04
Appears in 18 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Dr. Reddy's LabsDRREDDY | ₹1.02 L Cr | 36.60 | 2.73 | 11.6% | 13.0% | 11.0% | 0.20 | -5.5% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 5d agoHeadlines about Divi's Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 79.8
- EPS (TTM)
- ₹110.20
- Price / Book
- 14.18
- ROE (FY26)
- 16.2%
- ROCE (latest year)
- 22%
- Dividend yield
- 0.34%
Moving averages (NSE)
- 20-day
- ₹9,303.78
- Price below
- 50-day
- ₹9,155.89
- Price below
- 200-day
- ₹7,237.26
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- FII
- DII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Expenses | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 |
| Operating Profit | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 |
| OPM % | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% |
| Other Income | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 |
| Interest | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 |
| Profit before tax | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 |
| Tax % | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% |
| Net Profit | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| EPS in Rs | ₹13.11 | ₹13.49 | ₹20.27 | ₹16.20 | ₹19.21 | ₹22.19 | ₹24.94 | ₹20.53 | ₹25.95 | ₹21.96 | ₹28.29 | ₹33.98 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+15 days since Mar 2021
+17 days since Mar 2021
-11 days since Mar 2021
+43 days since Mar 2021
+43 days since Mar 2021
Strengths, risks & growth
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients [1]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.0%
Risks
- Stock is trading at 14.2 times its book value
- The company has delivered a poor sales growth of 8.67% over past five years.
Compounded Sales Growth
- 10 Years
- +11%
- 5 Years
- +9%
- 3 Years
- +11%
- TTM
- +16%
Compounded Profit Growth
- 10 Years
- +9%
- 5 Years
- +6%
- 3 Years
- +13%
- TTM
- +29%
Stock Price CAGR
- 10 Years
- +21%
- 5 Years
- +12%
- 3 Years
- +38%
- 1 Year
- +36%
Return on Equity
- 10 Years
- +18%
- 5 Years
- +17%
- 3 Years
- +15%
- Last Year
- +17%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 51.88% | 51.88% | 51.88% | 51.87% | -0.01 pp |
| FII | 20.08% | 20.29% | 20.19% | 20.38% | +0.19 pp |
| DII | 19.18% | 19.13% | 19.29% | 19.08% | -0.21 pp |
| Government | 0.09% | 0.09% | 0.09% | 0.09% | 0.00 pp |
| Public | 8.75% | 8.61% | 8.53% | 8.58% | +0.05 pp |
Filed with NSE for Sept 2026: promoters 51.88%, public 48.12% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 14.66% (+0.79 pp)- Promoters51.9%
- Foreign institutions20.4%
- Mutual funds14.7%
- Insurance3.5%
- Other domestic institutions1.0%
- Retail6.1%
- Others2.5%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Large Cap Fund | 0.78% | 3.61% | +1.18 pp |
| HDFC Flexi Cap Fund | 0.76% | 1.62% | +0.51 pp |
| SBI Aggressive Hybrid Fund | 0.65% | 1.83% | +0.07 pp |
| SBI Focused Fund | 0.50% | 2.41% | +0.22 pp |
| Axis ELSS-Tax Saver Fund | 0.37% | 2.74% | +0.67 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 24.1%
- Downside volatility
- 21.1%
- Worst 5% of days
- 2.4%
- Average of that tail
- 2.8%
- Max drawdown (1Y)
- 15.4%
- Below its peak
- 7.0%
Against the market
- Beta vs Nifty 50
- 0.62
- Correlation
- 0.34
- Relative strength (3M)
- +27.8%
- ATR (14)
- 2.6%
Return
- Return 1M
- -4.3%
- Return 3M
- +22.5%
- Return 6M
- +42.4%
- Return 1Y
- +36.4%
- vs 200-day average
- +23.7%
Momentum
- RSI (14)
- 41.5
- MACD histogram
- -57.99
- Stochastic %K
- 17.7
- ADX (14)
- 21.3
- +DI / −DI
- 17.1 / 25.6
- Money flow index
- 38.9
Participation
- Delivery (20d avg)
- 64.4%
- vs its 60-day baseline
- +3.1 pts
- Volume vs 20-day
- +0.3σ
- Close vs day's VWAP
- +0.5%
- 52-week position
- 83 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹218 Cr
- FCF yield
- 0.1%
- Cash conversion
- 1.07
- Accruals ratio
- -0.008
- Net debt
- -₹121 Cr
- Net debt / equity
- -0.01
- EV / sales
- 21.15
- PEG
- 6.04
- Capex intensity
- 23.9%
- Revenue CAGR
- 9.5%
- Profit CAGR
- 13.4%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Model simulation
30 independent runs of NeoQuasar/Kronos-small, conditioned on daily bars to 23 Oct 2026, simulating 10 sessions ahead.
Lower edge (10th percentile)
₹7,248.83
-19.0%
Upper edge (90th percentile)
₹8,042.11
-10.1%
The marker is the last close, ₹8,950. Eight of every ten simulated runs ended inside this range; the middle run ended at ₹7,687.37 (-14.1%), which is the centre of the simulation and not an expected or target price.
The model reads price history only. It has not seen this company's results, its filings, its industry or anything that happened after 23 Oct 2026. Ranges widen with horizon because the further out the simulation runs, the less the recent past constrains it.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
L. Sri Lakshmi Immediate Relative · Market Purchase | Buy | 162 | ₹15.3 L | 30 Sept 2026 |
D Radhika Immediate Relative · Market Purchase | Buy | 300 | ₹28.0 L | 30 Sept 2026 |
Nimmagadda Venkata Anirudh Designated Person · Pledge Creation | Pledge | 3,500 | ₹3.3 Cr | 30 Sept 2026 |
Joshita Divi Designated Person · Market Purchase | Buy | 1,005 | ₹96.1 L | 30 Sept 2026 |
L. Sri Lakshmi Immediate Relative · Market Purchase | Buy | 603 | ₹57.9 L | 26 Sept 2026 |
PRASAD Y.T.S. Designated Person · Pledge Release | Pledge | 734 | ₹69.3 L | 25 Sept 2026 |
PRASAD Y.T.S. Designated Person · Pledge Release | Pledge | 2,000 | ₹1.9 Cr | 25 Sept 2026 |
PRASAD Y.T.S. Designated Person · Market Sale | Sell | 6,234 | ₹5.8 Cr | 12 Sept 2026 |
K. Sridevi Immediate Relative · Market Sale | Sell | 200 | ₹19.0 L | 11 Sept 2026 |
K. Sridevi Immediate Relative · Market Sale | Sell | 200 | ₹18.6 L | 8 Sept 2026 |
K. Sridevi Immediate Relative · Market Sale | Sell | 200 | ₹18.5 L | 31 Aug 2026 |
K. Sridevi Immediate Relative · Market Sale | Sell | 200 | ₹17.7 L | 28 Aug 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹30.00
Dividend - Rs 30 Per Share
24 Jul 2026ex-date - dividend₹30.00
Dividend - Rs 30 Per Share
25 Jul 2025ex-date - dividend₹30.00
Dividend - Rs 30 Per Share
2 Aug 2024ex-date - dividend₹30.00
Dividend - Rs 30 Per Share
11 Aug 2023ex-date - dividend₹30.00
Dividend - Rs 30 Per Share
11 Aug 2022ex-date - dividend₹20.00
Dividend - Rs 20 Per Share
17 Aug 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
4 Sept 2020ex-date - dividend₹16.00
Interim Dividend - Rs 16 Per Share
25 Feb 2020ex-date - dividend₹16.00
Annual General Meeting/Dividend - Rs 16 Per Share
14 Aug 2019ex-date - dividend₹10.00
Annual General Meeting/Dividend- Rs 10 Per Share
31 Aug 2018ex-date - dividend₹10.00
Annual General Meeting/Dividend - Rs 10/- Per Share
15 Sept 2017ex-date - otherNot available — not reported in this filing
Annnual General Meeting
18 Aug 2016ex-date - dividend₹10.00
Interim Dividend - Rs 10/- Per Share (Purpose Revised)
17 Mar 2016ex-date - bonusNot available — not reported in this filing
Bonus 1:1
23 Sept 2015ex-date - dividend₹20.00
Annual General Meeting/Dividend - Rs 20/- Per Share
6 Aug 2015ex-date - dividend₹20.00
Annual General Meeting / Dividend - Rs 20/- Per Share
31 Jul 2014ex-date - dividend₹15.00
Annual General Meeting/Dividend Rs 15/- Per Share
25 Jul 2013ex-date - dividend₹13.00
Annual General Meeting/ Dividend Of Rs. 13 Per Share
26 Jul 2012ex-date - dividend₹10.00
Annual General Meeting And Dividend Rs.10/- Per Share
16 Jun 2011ex-date - dividend₹6.00
Annual General Meeting And Dividend Rs.6/- Per Share
2 Jul 2010ex-date
Company announcements
Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
Intimation of closure of Trading Window from 01.10.2026 till 48 hours of declaration of financial results for the quarter and half year ended 30.09.2026.
Newspaper Clippings - Special Window for transfer and dematerialisation of physical shares
Submission of Scrutinizer's report on 36th AGM resolutions.
Outcome of 36th AGM - submission of AGM proceedings, voting results and Scrutinizer's report.
Submission of transcript of Earnings Conference Call held on August 01, 2026
Newspaper clippings regarding unaudited financial results of the Company for the quarter ended June 30, 2026
Intimation of Q1FY27 earnings call audio recording.
As per enclosed letter.
Outcome of Board meeting held on August 01, 2026.
Intimation of retirement of Senior Management Personnel as detailed in the enclosed letter.
Schedule of earnings conference call for Q1 FY27
Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve the unaudited financial ....
Newspaper Clippings - Notice of 36th AGM, e-voting & other information
Filed with BSE (scrip 532488); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Aug 2026TranscriptRecording
- May 2026Transcript
- Feb 2026TranscriptRecording
- Nov 2025TranscriptRecording
- Aug 2025Transcript
- May 2025Transcript
Credit ratings
- Rating update · 7 Sep from care
- Rating update · 26 Aug 2025 from care
- Rating update · 13 Sep 2024 from care
- Rating update · 12 Sep 2023 from care
- Rating update · 4 Oct 2022 from care
- Rating update · 5 Oct 2021 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 1 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Divi's Laboratories: common questions
Answered from the figures on this page.
